Liraglutide is a recombinant peptide analogue of human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist. It is a long-acting lipopeptide designed to mimic the activity of endogenous GLP-1 while providing prolonged receptor activity.
Liraglutide contains a GLP-1-derived peptide backbone with a C16 palmitoyl fatty-acid chain attached through a glutamic-acid spacer. This structural modification contributes to its prolonged pharmacological activity.
Liraglutide (Recombinant) is a specialized peptide pharmaceutical API requiring controlled recombinant/biotechnological production, purification and extensive analytical characterization.
Critical quality attributes include identity, peptide purity, related peptides, aggregation, water content, residual solvents, peptide content and biological activity.
CAS Number: 204656-20-2
Molecular Formula: C172H265N43O51
Molecular Weight: 3751 g/mol
Synonym: NN2211
Drug Class: GLP-1 Receptor Agonist
Therapeutic Class: Antidiabetic / Anti-obesity Agent
Molecule Type: Synthetic/Modified Peptide Lipopeptide
Therapeutic Area: Diabetes / Metabolic Disorders
Liraglutide acts as an agonist of the GLP-1 receptor. GLP-1 receptor activation contributes to glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and delayed gastric emptying.
Its prolonged activity compared with native GLP-1 results from structural modifications that increase resistance to enzymatic degradation and extend circulation time.
Liraglutide is associated with pharmaceutical formulations used for:
Liraglutide is derived from human GLP-1 and contains specific structural modifications, including:
The resulting lipopeptide has a molecular weight of approximately 3.75 kDa.
A controlled recombinant/peptide manufacturing process may include:
Typical Liraglutide API testing may include:
Store Liraglutide API under validated temperature and humidity conditions, protected from excessive heat, moisture and light. Because Liraglutide is a peptide, storage conditions should be based on the actual manufacturer's validated stability data and approved specification.
Liraglutide is relevant to research involving:
Liraglutide is a long-acting GLP-1 receptor agonist peptide with CAS 204656-20-2, molecular formula C172H265N43O51, and molecular weight approximately 3751 g/mol. It is a modified GLP-1 analogue containing a palmitoyl group attached through a glutamic-acid spacer.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 95.0% |
| Loss on Drying | NMT 5.0% |
| Water Content | NMT 5.0% |